NCT03737994 2026-03-18
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
4 trialsNCT03420742 2023-01-27
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors
Takeda
Phase 1 Completed
NCT04634110 2022-10-24
Brigatinib Before Brain Irradiation Trial (B3i Trial)
University of Colorado, Denver
Phase 2 Terminated
NCT02737501 2021-08-20
ALTA-1L
Takeda
Phase 3 Completed